Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Platinum-sensitive ovarian cancer, drawn from the whole corpus: 25 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether HRD-negative tumours gain enough from PARP inhibitors to justify two to three years of treatment.
Resistance through BRCA reversion and restored homologous recombination.
How long to continue maintenance, and whether circulating tumour DNA can tell.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 16 changes by month →When this page itself was last checked or edited.
PFS HR 0.
A milestone in how this cancer is treated.
PFS 20.
A milestone in how this cancer is treated.
OS 53.